Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.
Horizon Therapeutics is gaining global rights to an Arrowhead Pharmaceuticals drug for gout. The preclinical drug is the latest RNA interference program that Arrowhead has licensed to a larger pharma company.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also, an FDA panel has rejected Sarepta Therapeutics' Duchenne muscular dystrophy treatment, and Zimmer Biomet Holdings will acquire Cayenne Medical.
With support from Sanofi and the Juvenile Diabetes Research Foundation, Boston-based Selecta Biosciences has raised $20 million to advance drug candidates for Type 1 diabetes and severe gout. Of the gout program, CEO Werner Cautreels said in a statement: “SEL-212 is just the beginning for us, as we have identified many biopharmaceuticals, including existing and new classes of […]